Vascular Biogenics Performance
| VBLTDelisted Stock | USD 0.28 0.01 3.45% |
The entity has a beta of -0.52, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Vascular Biogenics are expected to decrease at a much lower rate. During the bear market, Vascular Biogenics is likely to outperform the market. Vascular Biogenics right now has a risk of 0.0%. Please validate Vascular Biogenics sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to decide if Vascular Biogenics will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Vascular Biogenics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable essential indicators, Vascular Biogenics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 22.3 M | |
| Free Cash Flow | -32.4 M |
Vascular |
Vascular Biogenics Relative Risk vs. Return Landscape
If you would invest 28.00 in Vascular Biogenics on September 13, 2024 and sell it today you would earn a total of 0.00 from holding Vascular Biogenics or generate 0.0% return on investment over 90 days. Vascular Biogenics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Vascular, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vascular Biogenics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vascular Biogenics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vascular Biogenics, and traders can use it to determine the average amount a Vascular Biogenics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| VBLT |
Based on monthly moving average Vascular Biogenics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vascular Biogenics by adding Vascular Biogenics to a well-diversified portfolio.
Vascular Biogenics Fundamentals Growth
Vascular Stock prices reflect investors' perceptions of the future prospects and financial health of Vascular Biogenics, and Vascular Biogenics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vascular Stock performance.
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (33.89) % | |||
| Current Valuation | (10.99 M) | |||
| Shares Outstanding | 77.64 M | |||
| Price To Earning | (9.32) X | |||
| Price To Book | 0.35 X | |||
| Price To Sales | 9.63 X | |||
| Revenue | 658 K | |||
| EBITDA | (31.16 M) | |||
| Cash And Equivalents | 34.15 M | |||
| Cash Per Share | 0.49 X | |||
| Total Debt | 564 K | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (31.59 M) | |||
| Earnings Per Share | (0.18) X | |||
| Total Asset | 29.66 M | |||
| Retained Earnings | (294.38 M) | |||
| Current Asset | 38.59 M | |||
| Current Liabilities | 4.16 M | |||
About Vascular Biogenics Performance
Assessing Vascular Biogenics' fundamental ratios provides investors with valuable insights into Vascular Biogenics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vascular Biogenics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.Things to note about Vascular Biogenics performance evaluation
Checking the ongoing alerts about Vascular Biogenics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vascular Biogenics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vascular Biogenics is not yet fully synchronised with the market data | |
| Vascular Biogenics has some characteristics of a very speculative penny stock | |
| Vascular Biogenics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 658 K. Net Loss for the year was (32.3 M) with profit before overhead, payroll, taxes, and interest of 554 K. | |
| Vascular Biogenics currently holds about 34.15 M in cash with (31.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 13.0% of the company outstanding shares are owned by insiders |
- Analyzing Vascular Biogenics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vascular Biogenics' stock is overvalued or undervalued compared to its peers.
- Examining Vascular Biogenics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vascular Biogenics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vascular Biogenics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vascular Biogenics' stock. These opinions can provide insight into Vascular Biogenics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |